|
References: C
- Campbell, M., and J. E. Cueva. 1995. Psychopharmacology in child and adolescent psychiatry: A review of the past seven years. Part I. J. Am. Acad. Child Adolesc. Psychiatry 34:1124-1132.
- Campbell, M., P. B. Adams, A. M. Small, V. Kafantaris, R. R. Silva, J. Shell, R. Perry, and J. E. Overall. 1995. Lithium in hospitalized aggressive children with conduct disorder: A double-blind and
placebo-controlled study. J. Am. Acad. Child Adolesc. Psychiatry 34:445-463.
- Cantwell, D. P., J. Swanson, and D. F. Connor. 1997. Case study: Adverse response to clonidine. J. Am. Acad. Child Adolesc. Psychiatry 36:539-544.
- Carpenter, N. J., D. H. Barber, M. Jones, W. Lindley, and C. Carr. 1983. Controlled six-month study of oral folic acid therapy in boys with fragile X-linked mental retardation [abstract 243]. Am. J.
Hum. Genet. (Suppl.) 35:82A.
- Chandran, K. S. K. 1994. ECG and clonidine. J. Am. Acad. Child Adolesc. Psychiatry 33:1351-1352.
- Comings, D. E., B. F. Comings, T. Tacket, and S. Li. 1990. The clonidine patch and behavior problems. J. Am. Acad. Child Adolesc. Psychiatry 29:667-668.
- Conners, C. K. 1973. Rating scales for use in drug studies with children. Psychopharmacol. Bull., special issue, pp. 24-84, 219-222.
- Conners, C. K., C. D. Casat, C. T. Gualtieri, E. Weller, M. Reader, A. Reiss, R. A. Weller, M. Khayrallah, and J. Ascher. 1996. Bupropion hydrochloride in attention deficit disorder with hyperactivity.
J. Am. Acad. Child Adolesc. Psychiatry 35:1314-1321.
- Connor, D. F., K. R. Ozbayrak, K. A. Kusiak, A. B. Caponi, and R. H. Melloni Jr. 1997. Combined pharmacotherapy in children and adolescents in a residential treatment center [see comments]. J. Am.
Acad. Child Adolesc. Psychiatry 36:248-254.
- Constantino, J. N. 1995. Testosterone and aggression [letter]. J. Am. Acad. Child Adolesc. Psychiatry 34:535.
- Cook, E. H., Jr., R. Rowlett, C. Jaseiskis, and B. L. Leventhal. 1992. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J. Am. Acad. Child Adolesc. Psychiatry
31:739-750.
|
This article is not intended to give medical advice for individual cases. Any change in medical treatment
should be done in consultation with appropriate medical personnel. This article is written for medical professionals. Some of the terms will be unfamiliar to those who are not trained in medical fields.
*This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited
by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002. It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in
the book which are not included as part of this website.
The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling
1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.
|
|
Medical Follow-up Pharmacotherapy Future Prospects
Outline Medications Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
|
|
